AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Nektar Therapeutics (NASDAQ:NKTR)
0.67685 USD
+0.002 0.304%| Previous Close (in USD) | 0.6748 |
|---|---|
| Change | +0.002 0.304% |
| 52 W H/L (in USD) | 1.928/0.413 |
| EBITDA (in USD) | -125.541M |
| PE Ratio | -- |
| Volume | 705037 |
| Diluted Eps TTM | -0.91 |
| Total Assets (in USD) | 398.033M |
|---|---|
| Total Liabilities (in USD) | 267.046M |
| Revenue TTM (in USD) | 90.167M |
| Cash (in USD) | 20.161M |
| Market Cap (in USD) | 275.438 M |
| Revenue Per Share TTM | 0.471 |
| Gross Profit TTM (in USD) | 70.42M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
415 482 5300
Employees: 137
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Howard W. Robin | CEO, Pres & Director | 1953 |
| 2. | Mr. Mark A. Wilson | Chief Legal Officer & Sec. | 1972 |
| 3. | Dr. Jonathan Zalevsky Ph.D. | Sr. VP & Chief R&D Officer | 1975 |
| 4. | Mr. John P. Northcott | Strategic Consulting Advisor | 1978 |
| 5. | Ms. Jillian B. Thomsen | Chief Financial Officer | 1966 |
| 6. | Mr. Robert Bacci | Sr. VP of HR & Facilities Operations | NA |
| 7. | Ms. Jennifer Ruddock | Chief Bus. Officer | NA |
| 8. | Dr. Mary Tagliaferri L.Ac., M.D. | Chief Devel. Officer | 1966 |
| 9. | Dr. Brian L. Kotzin M.D. | Chief Medical Officer | 1949 |
| 10. | Dr. Kevin Brodbeck Ph.D. | Sr. VP of Technical Operations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -364.983M | -523.28M | -443.947M | -440.054M | 682.725M |
| Minority Interest | - | - | - | - | - |
| Net Income | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
| Selling General Administrative | 92.333M | 122.844M | 104.682M | 98.712M | 81.443M |
| Gross Profit | 70.42M | 77.01M | 133.438M | 93.243M | 1168.911M |
| Reconciled Depreciation | 13.03M | 14.146M | 14.182M | 13.156M | 10.87M |
| Ebit | -240.236M | -446.103M | -379.922M | -440.035M | 725.503M |
| Ebitda | -220.539M | -453.798M | -347.458M | -380.544M | 736.373M |
| Depreciation And Amortization | 19.697M | -7.695M | 32.464M | 59.491M | 10.87M |
| Operating Income | -240.236M | -446.103M | -379.922M | -440.035M | 687.932M |
| Other Operating Expenses | 332.291M | 548.01M | 532.837M | 554.652M | 505.391M |
| Interest Expense | 28.911M | 47.313M | 37.118M | 46.354M | 42.778M |
| Tax Provision | 3.215M | 0.557M | 0.493M | 0.613M | 1.412M |
| Interest Income | 6.667M | 2.569M | 18.282M | 46.335M | 37.571M |
| Net Interest Income | -22.244M | -44.744M | -18.836M | -0.019M | -5.207M |
| Income Tax Expense | 3.215M | 0.557M | 0.493M | 0.613M | 1.412M |
| Total Revenue | 92.055M | 101.907M | 152.915M | 114.617M | 1193.323M |
| Total Operating Expenses | 310.656M | 523.113M | 513.36M | 533.278M | 480.979M |
| Cost Of Revenue | 21.635M | 24.897M | 19.477M | 21.374M | 24.412M |
| Total Other Income Expense Net | -124.747M | -77.177M | -64.025M | -0.019M | -5.207M |
| Net Income From Continuing Ops | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
| Net Income Applicable To Common Shares | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 398.033M | 710.6M | 1117.189M | 1538.767M | 1977.356M |
| Intangible Assets | - | - | - | - | 26.91M |
| Other Current Assets | 8.732M | 15.808M | 23.333M | 18.02M | 15.387M |
| Total Liab | 267.046M | 343.962M | 437.681M | 461.472M | 571.965M |
| Total Stockholder Equity | 130.987M | 366.638M | 679.508M | 1077.295M | 1405.391M |
| Other Current Liab | 22.162M | 36.557M | 58.012M | 79.634M | 67.933M |
| Common Stock | 0.019M | 0.019M | 0.019M | 0.018M | 0.017M |
| Capital Stock | 0.019M | 0.019M | 0.019M | 0.018M | 0.017M |
| Retained Earnings | -3477.249M | -3201.193M | -2832.995M | -2309.158M | -1864.718M |
| Good Will | 0M | 76.501M | 76.501M | 76.501M | 76.501M |
| Other Assets | - | 2.245M | 2.744M | 264.599M | 1.01M |
| Cash | 20.161M | 88.227M | 25.218M | 198.955M | 96.363M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 51.269M | 68.204M | 85.2M | 115.779M | 353.893M |
| Current Deferred Revenue | - | - | - | 0.091M | 5.517M |
| Net Debt | 210.24M | 43.269M | 117.959M | -48.667M | 307.576M |
| Short Term Debt | 19.259M | 18.667M | 17.441M | 13.915M | 261.209M |
| Short Long Term Debt | - | - | - | - | 248.693M |
| Short Long Term Debt Total | 230.401M | 131.496M | 143.177M | 150.288M | 403.939M |
| Other Stockholder Equity | 3608.137M | 3574.719M | 3516.641M | 3388.73M | 3271.097M |
| Property Plant Equipment | - | 85.886M | 177.535M | 59.662M | 64.999M |
| Total Current Assets | 330.701M | 545.968M | 795.581M | 1138.005M | 1421.55M |
| Long Term Investments | 25.825M | 0M | 64.828M | 136.662M | 279.119M |
| Short Term Investments | 283.455M | 416.75M | 708.737M | 862.941M | 1228.499M |
| Net Receivables | 2.252M | 5.981M | 22.492M | 38.889M | 36.802M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 16.101M | 19.202M | 15.801M | 15.292M | 12.665M |
| Accounts Payable | 9.848M | 12.98M | 9.747M | 22.139M | 19.234M |
| Accumulated Other Comprehensive Income | 0.08M | -6.907M | -4.157M | -2.295M | -1.005M |
| Non Currrent Assets Other | 4.644M | 2.245M | 2.744M | 1.461M | 1.01M |
| Non Current Assets Total | 67.332M | 164.632M | 321.608M | 400.762M | 555.806M |
| Capital Lease Obligations | 117.776M | 131.496M | 143.177M | 150.288M | 155.246M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 365.835M | 217.766M | 503.471M | 233.171M | -1368.33M |
| Total Cashflows From Investing Activities | 365.835M | 202.777M | 496.213M | 206.886M | -1379.936M |
| Total Cash From Financing Activities | 1.508M | 36.238M | -80.354M | 23.355M | 851.966M |
| Net Income | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
| Change In Cash | 63.009M | -173.737M | 102.592M | -98.542M | 190.143M |
| Begin Period Cash Flow | 25.218M | 198.955M | 96.363M | 194.905M | 4.762M |
| End Period Cash Flow | 88.227M | 25.218M | 198.955M | 96.363M | 194.905M |
| Total Cash From Operating Activities | -304.007M | -412.66M | -313.287M | -328.681M | 718.214M |
| Depreciation | 13.03M | 14.146M | 14.182M | 13.156M | 10.87M |
| Other Cashflows From Investing Activities | - | - | - | 233.171M | 2.633M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -3.401M | -0.509M | -2.627M | -1.284M | -0.655M |
| Sale Purchase Of Stock | - | 33.238M | 23.396M | 23.355M | 851.966M |
| Other Cashflows From Financing Activities | 1.508M | 36.238M | 169.646M | 23.355M | 61.735M |
| Capital Expenditures | 5.676M | 14.989M | 7.258M | 26.285M | 14.239M |
| Change In Working Capital | 0.492M | -23.076M | 16.712M | 21.688M | -39.006M |
| Other Non Cash Items | -9.359M | 17.41M | -14.353M | -22.653M | -23.064M |
| Free Cash Flow | -309.683M | -427.649M | -320.545M | -354.966M | 703.975M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 5724732 |
| 2. | PRIMECAP Odyssey Aggressive Growth | 1 year ago | 4233380 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 2676857 |
| 4. | PRIMECAP Odyssey Growth | 1 year ago | 2072356 |
| 5. | Vanguard Strategic Equity Inv | 1 year ago | 1517103 |
| 6. | Fidelity Extended Market Index | 1 year ago | 1061973 |
| 7. | BlackRock Advantage Small Cap Core Instl | 1 year ago | 969915 |
| 8. | Schwab US Small-Cap ETF™ | 1 year ago | 912965 |
| 9. | Vanguard Strategic Small-Cap Equity Inv | 1 year ago | 763309 |
| 10. | Vanguard Health Care ETF | 1 year ago | 640997 |
| 11. | BlackRock Extended Mkt Composite | 1 year ago | 538851 |
| 12. | Invesco FTSE RAFI US 1500 Small-Mid ETF | 1 year ago | 532085 |
| 13. | Vanguard US Opportunities Ins USD Acc | 1 year ago | 521011 |
| 14. | BlackRock Extended Equity Market K | 1 year ago | 470272 |
| 15. | Fidelity Total Market Index | 1 year ago | 331350 |
| 16. | Vanguard Market Neutral I | 1 year ago | 261128 |
| 17. | Delaware Healthcare I | 1 year ago | 256385 |
| 18. | Fidelity Series Total Market Index | 1 year ago | 247674 |
| 19. | Blackrock Russell 2000 Alpha Tilts Fd A | 1 year ago | 228015 |
| 20. | Multi-Manager Small Cap Eq Strat Inst | 1 year ago | 219719 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Deep Track Capital, LP | 1 year ago | 18400000 |
| 2. | Vanguard Group Inc | 1 year ago | 12049138 |
| 3. | Acadian Asset Management LLC | 1 year ago | 7569063 |
| 4. | PRIMECAP Management Company | 1 year ago | 6966647 |
| 5. | BlackRock Inc | 1 year ago | 6104217 |
| 6. | Monaco Asset Management | 1 year ago | 5831565 |
| 7. | Renaissance Technologies Corp | 1 year ago | 5325475 |
| 8. | Stonepine Capital Management Llc | 1 year ago | 3480409 |
| 9. | Millennium Management LLC | 1 year ago | 2984545 |
| 10. | D. E. Shaw & Co LP | 1 year ago | 2548990 |
| 11. | Nantahala Capital Management, LLC | 1 year ago | 2475954 |
| 12. | Two Sigma Advisers, LLC | 1 year ago | 2240342 |
| 13. | Two Sigma Investments LLC | 1 year ago | 2081940 |
| 14. | Shay Capital LLC | 1 year ago | 2079674 |
| 15. | Geode Capital Management, LLC | 1 year ago | 2039614 |
| 16. | GSA Capital Partners LLP | 1 year ago | 1989905 |
| 17. | Jacobs Levy Equity Management, Inc. | 1 year ago | 1911186 |
| 18. | Goldman Sachs Group Inc | 1 year ago | 1727738 |
| 19. | Assenagon Asset Management SA | 1 year ago | 1687300 |
| 20. | Marshall Wace Asset Management Ltd | 1 year ago | 1471237 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...